Rockpointe CFTR Mutation and Function: Advances in Scientific Knowledge - RICHARD B. MOSS a href="">Emerging Mutation-Specific Therapies in Cystic Fibrosis - PATRICK A. FLUME, MD a href="">Advancing Pulmonary Management in Cystic Fibrosis - MARCIA F. KATZ, MD, FCCP a href="">Advancing GI and Nutritional Management in Cystic Fibrosis - VIRGINA A. STALLINGS, MD

View this Series of CME-certified Activities Designed for Pulmonary and Gastrointestinal Specialists who Manage Patients with Cystic Fibrosis

Cystic fibrosis (CF) is the most common life-shortening, inheritable disease in Caucasians. Although life expectancy for those with CF has increased markedly over the last few decades, mainly due to improvements in treating end-organ manifestations, median predicted survival is only now approaching 40 years. Clearly, there is further room to improve survival and lower the high treatment burden for the 30,000 people living with CF in the US.

Recent advances in scientific knowledge have allowed the development of agents capable of overcoming the CFTR processing errors caused by genetic mutations and improving the cellular function of affected cells. This is a marked departure from previous therapeutic approaches focused solely on delaying the development of end-organ damage. It is critically important that the clinicians caring for individuals with CF are aware of these latest scientific advances and have the knowledge and skills needed to incorporate these newer therapies into clinical practice as they become available.

Target Audience This series of four CME-certified activities was designed to provide pulmonary and gastrointestinal specialists who manage patients with CF access to the latest scientific information and clinical trial data on treatments designed to improve CFTR function, and possibly prevent or delay end-organ damage.
CFTR Mutation and Function: Advances in Scientific Knowledge

Description - Dr. Moss discusses the processing and function of CFTR and explains how different mutations in the gene encoding the CFTR protein lead to different variants of cystic fibrosis with varying levels of disease severity.

Presented by:
Professor Emeritus of Pediatrics
Center for Excellence in Pulmonary Biology
Stanford University
Palo Alto, CA
Emerging Mutation-Specific Therapies in Cystic Fibrosis

Description - Dr. Flume discusses the current and emerging agents designed to overcome CFTR dysfunctions imposed by specific cystic fibrosis mutations.

Presented by:
Professor of Medicine and Pediatrics
Department of Pulmonary Medicine
Director of the Medical University of South Carolina CF Center
Charleston, SC
Advancing Pulmonary
Management in Cystic Fibrosis

Description - Dr. Katz describes the pulmonary damage that results from CFTR malfunction and the progress that has been made in preventing and delaying the resultant lung disease. Integration of new and emerging agents into current management protocols is also discussed.

Presented by:
Associate Chair of Medicine for Clinical Affairs
The Brown Foundation Professor of Adult Cystic Fibrosis
Director, Adult Cystic Fibrosis Center
Associate Professor of Medicine
Head of Adult Medicine for the Texas Children’s Hospital
Pavilion for Women
Baylor College of Medicine, Houston, TX
Advancing GI and Nutritional Management in Cystic Fibrosis

Description - Dr. Stallings describes the GI and nutritional deficiencies that occur in patients with cystic fibrosis and reviews the latest information needed to improve the management of these deficiencies.

Presented by:
Professor of Pediatrics
University of Pennsylvania Perelman School of Medicine
Director of the Nutrition Center
Director of the Office of Faculty Development
The Children’s Hospital of Philadelphia Research Institute
Philadelphia, PA

Jointly sponsored by         Supported by an independent educational grant from
©2013 Rockpointe